WGC
ABBV icon

Watts Gwilliam & Co’s AbbVie ABBV Stock Holding History

Watts Gwilliam & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.9M Buy
16,857
+27
+0.2% +$5.5K 0.63% 30
2025
Q2 		$3.74M Buy
16,830
+463
+3% +$86K 0.61% 31
2025
Q1 		$3.43M Buy
16,367
+181
+1% +$35.2K 0.74% 33
2024
Q4 		$2.91M Buy
16,186
+70
+0.4% +$12.9K 0.61% 38
2024
Q3 		$3.11M Buy
+16,116
New +$3.01M 0.68% 33
2024
Q1 		$2.13M Buy
+13,194
New +$2.27M 0.66% 33

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Watts Gwilliam & Co's ABBV Position: Q3 2025 in Review

Watts Gwilliam & Co increased its AbbVie (ABBV) stake by 0.16% in Q3 2025, buying an estimated $5.5K and bringing the position to 16,857 shares worth $3.9M. The position accounts for 0.63% of the portfolio, ranked #30.

Watts Gwilliam & Co first reported a position in ABBV in Q1 2024 and has held it in 6 quarters since. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Watts Gwilliam & Co held 16,857 shares of AbbVie worth $3.9M as of Q3 2025.
  • Watts Gwilliam & Co bought 27 AbbVie shares in Q3 2025, an estimated $5.5K.
  • AbbVie made up 0.63% of Watts Gwilliam & Co's portfolio in Q3 2025, its #30 holding.
  • Watts Gwilliam & Co first reported a position in AbbVie in Q1 2024 and has held it in 6 quarters since.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Watts Gwilliam & Co's 13F filing for Q3 2025, filed 21 Nov 2025.